Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Latest Interferon beta-1a Stories

2013-03-21 04:20:42

-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1 EAST HANOVER, N.J., March 21, 2013 /PRNewswire/ -- New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya(®) (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently...

2013-03-10 23:01:33

The http://www.SclerosisTreatment.com website, a division of Ironclad Integrity Ltd., reveals a new therapy based on plants, vitamins and correct nutrition to reduce fatigue, pain and other MS symptoms instead of drug intake. Denver, Colorado (PRWEB) March 10, 2013 According to http://www.Sclerosistreatment.com for the 2.5 million MS patients worldwide, the lack of a permanent cure for their condition is frustrating and puzzling. Conventional therapies to treat Multiple Sclerosis are based...

2013-01-03 12:24:27

ROCKLAND, Mass. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif(®) Rebidose(®) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo:...

New Treatment For Multiple Sclerosis Offers Promising Results
2012-11-01 09:25:28

Lawrence LeBlond for redOrbit.com - Your Universe Online A new drug to fight multiple sclerosis (MS) is showing promise as one of the “most effective” treatment options ever produced for the debilitating disease, according to UK researchers. The drug, which is used to ℠reboot´ a person´s immune system, has been shown to be effective in MS patients who have already failed to respond to the first drug with which they were treated, as well as those who have gone...

2012-04-23 04:45:20

(Ivanhoe Newswire) — According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo. Although it is not currently available in the United States, the trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is available in all European Union...

2012-04-20 10:05:05

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New...

2012-04-19 10:26:33

NEW ORLEANS, April 19, 2012 /PRNewswire-USNewswire/ -- People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the...

2012-03-07 13:00:00

ST. PAUL, Minn., March 7, 2012 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), and EMD Serono, Inc., a leader in the U.S. biopharmaceutical market and subsidiary of Merck KGaA, Darmstadt, Germany, have entered into an agreement bringing the first outcomes-based rebate contract for a multiple sclerosis (MS) drug to Prime's CareCentered Contracting program. As an integrated PBM with its health plan clients, Prime is uniquely positioned to ensure members are...

2012-01-23 07:00:00

ROCKLAND, Mass. and NEW YORK, Jan. 23, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the MS LifeLines® call center earned certification through the prestigious J.D. Power and Associates Call Center Program(SM)( )after a thorough audit of customer satisfaction practices over several months in 2011. This is the first time J.D. Power and Associates has recognized a pharmaceutical call center for...

2011-12-12 03:30:00

ALBANY, New York, December 12, 2011 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) [http://www.researchmoz.com/biosimilar-follow-on-biologics-market-report-and-forecast-a-focus-on-the-us-2011-2020-report.html ] Published by IMARC [http://www.researchmoz.com/publisher/imarc-25.html ]. With sales worth US$ 57 Million in 2010, biosimilars are still far from their...